Celgene Corp.'s Revlimid (lenalidomide) is the top-selling drug approved for multiple myeloma by far and will remain a blockbuster long after generics become available in 2022. It will maintain such a strong presence, in fact, that the top brand in 2026 will generate a fraction of Revlimid's peak sales.
Datamonitor Healthcare's latest multiple myeloma market forecast suggests that drug sales for this disease will grow from $11.9bn in 2017 to $20.9bn in 2022 then drop each year after settling at $17bn in 2026 in the US, five major EU markets (France, Germany, Italy, Spain and the UK) and Japan. Johnson & Johnson's Darzalex (daratumumab) will be the top drug at the end of that 10-year period with $3
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?